FT. LAUDERDALE, Fla., July 30 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials announced today that a growing US Clinical Research Organization (CRO) has selected OmniComm to provide eClinical solutions in connection with two of the CRO's Phase IV studies covering approximately 27 sites and more than 700 subjects. Additional details were not disclosed. Phase IV studies take place after a drug has been approved for marketing and are designed to provide broader experience in evaluating the safety and effectiveness of the new medicine in larger numbers of patients, subpopulations of patients, and to compare and/or combine it with other available treatments.
"We are pleased to have been selected by this CRO to provide eClinical solutions for these important Phase IV studies," said Cornelis F. Wit, OmniComm's President and CEO. "We believe the broad scope of our integrated eClinical solutions, enhanced by the recent acquisition of eResearch Technology's data capture unit, positions us well to offer a broad array of solutions, especially for CRO's, pharmaceutical, biotech and medical device companies seeking cost-effective tools to capture and track outcomes of clinical trials conducted at multiple locations. We look forward to expanding the range of services we provide for companies seeking to increase efficiencies in their clinical activities."
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance
|SOURCE OmniComm Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved